Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance

2014 ◽  
Vol 29 (11) ◽  
pp. 2084-2091 ◽  
Author(s):  
Joëlle Guitard ◽  
Anne-Laure Hebral ◽  
Fadi Fakhouri ◽  
Dominique Joly ◽  
Eric Daugas ◽  
...  
The Lancet ◽  
1985 ◽  
Vol 325 (8425) ◽  
pp. 368-370 ◽  
Author(s):  
R.S. Trompeter ◽  
J. Hicks ◽  
B.W. Lloyd ◽  
R.H.R. White ◽  
J.S. Cameron

2013 ◽  
Vol 15 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Vickie Wai-Ki Kwong ◽  
Bonnie Ching-Ha Kwan ◽  
Kai-Ming Chow ◽  
Chi-Bon Leung ◽  
Philip Kam-Tao Li ◽  
...  

2019 ◽  
Vol 34 (11) ◽  
pp. 2417-2421
Author(s):  
Shuichiro Fujinaga ◽  
Daishi Hirano ◽  
Tomohiko Nishino ◽  
Chisato Umeda ◽  
Yoshitaka Watanabe ◽  
...  

2009 ◽  
Vol 4 (10) ◽  
pp. 1593-1600 ◽  
Author(s):  
Henriette A.C. Kyrieleis ◽  
Marije M. Löwik ◽  
Ilse Pronk ◽  
Hans R.M. Cruysberg ◽  
Jan A.M. Kremer ◽  
...  

2013 ◽  
Vol 79 (02) ◽  
pp. 101-106 ◽  
Author(s):  
Makoto Inoue ◽  
Wako Yumura ◽  
Yoshiyuki Morishita ◽  
Chiharu Ito ◽  
Yoshiaki Hamano ◽  
...  

1986 ◽  
Vol 29 (6) ◽  
pp. 1215-1223 ◽  
Author(s):  
Fernando Nolasco ◽  
J. Stewart Cameron ◽  
E.F. Heywood ◽  
Jackie Hicks ◽  
Chisholm Ogg ◽  
...  

2010 ◽  
Vol 25 (3) ◽  
pp. 539-544 ◽  
Author(s):  
Shuichiro Fujinaga ◽  
Daishi Hirano ◽  
Naoto Nishizaki ◽  
Koichi Kamei ◽  
Shuichi Ito ◽  
...  

2011 ◽  
Vol 64 (6) ◽  
pp. 516-519 ◽  
Author(s):  
Ji Hong Kim ◽  
Se Jin Park ◽  
So Jin Yoon ◽  
Beom Jin Lim ◽  
Hyeon Joo Jeong ◽  
...  

AimsTo identify the predictive factors for ciclosporin A (CyA)-associated nephrotoxicity (CAN) in children with minimal change nephrotic syndrome (MCNS).MethodsThe clinical and laboratory findings of 58 children (median age 3.2 years, range 1.1–13.1 years, male:female 48:10) with MCNS who were treated with CyA from 1992 to 2002 were analysed retrospectively. Forty-eight (83%) of them were steroid dependent and 10 (17%) were steroid resistant. The starting dose of CyA was 5 mg/kg per day, and the desired drug level was kept at 100–200 ng/ml. Serial renal biopsies were performed before and after CyA therapy.ResultsTwenty-two patients (38%) had CAN (group I) and 36 (62%) did not (group II). There were no differences in the age at onset, sex, initial response to steroids, duration of CyA therapy and relapse rates. However, the median CyA trough levels were significantly higher in group I than in group II (218.0±15.2 vs 171.8±6.7 ng/ml, p=0.01). Changes in creatinine clearance were more decreased in group I than in group II (−39.4±8.2 vs 2.7±4.3 ml/min per 1.73 m2, p<0.0001). Multiple logistic regression analysis also revealed the median CyA trough level was an independent risk factor for the development of CAN (OR 1.025, 95% CI 1.007 to 1.044, p=0.007).ConclusionsThe median CyA trough level was an independent and significant risk factor for the development of CAN in children with MCNS receiving moderate-dose CyA.


Sign in / Sign up

Export Citation Format

Share Document